دورية أكاديمية
A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma
| العنوان: | A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma |
|---|---|
| المساهمون: | Hyun Young Woo, Si Hyun Bae, Jun Yong Park, Kwang Hyub Han, Ho Jong Chun, Byung Gil Choi, Hyeon U. Im, Jong Young Choi, Seung Kew Yoon, Jae Youn Cheong, Sung Won Cho, Byoung Kuk Jang, Jae Seok Hwang, Sang Gyune Kim, Young Seok Kim, Yeon Seok Seo, Hyung Joon Yim, Soon Ho Um, Park, Jun Yong, Han, Kwang Hyup |
| سنة النشر: | 2010 |
| مصطلحات موضوعية: | Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma, Hepatocellular/drug therapy, Hepatocellular/mortality, Hepatocellular/pathology, Cisplatin/administration & dosage, Drug Administration Schedule, Female, Fluorouracil/administration & dosage, Hepatic Artery, Humans, Infusions, Intra-Arterial, Liver Neoplasms/drug therapy, Liver Neoplasms/mortality, Liver Neoplasms/pathology, Male, Middle Aged, Prognosis, Prospective Studies, Survival Rate, Hepatocellular carcinoma, Hepatic arterial infusion chemotherapy, High dose, Low dose 5-Fluorouracil Cisplatin |
| الوصف: | PURPOSE: Hepatic arterial infusion chemotherapy (HAIC) has been reported to be effective in patients with advanced hepatocellular carcinoma (HCC). METHODS: In this multicenter, prospective, open-labeled, clinical trial, we randomly assigned 68 patients with advanced HCC to receive either low-dose [n = 32, 5-fluorouracil (FU), 170 mg/m(2) and cisplatin, 7 mg/m(2) on days 1-5] or high-dose HAIC (n = 36, 5-FU, 500 mg/m(2) on days 1-3 and cisplatin, 60 mg/m(2) on day 2) every 4 weeks via an implantable port system. RESULTS: A total of 207 cycles of HAIC was given to the 68 patients. Overall, 6 patients (8.8%) achieved a partial response and 21 patients (30.9%) had stable disease. The objective response rate (CR + PR) was significantly improved in the high-dose group compared to the low-dose group (16.7% vs. 0%, P = 0.024). The median time to disease progression and overall survival were slightly prolonged in the high-dose group compared to the low-dose group (median survival, 193 vs. 153 days; P = 0.108; median time to disease progression, 145 vs. 90 days; P = 0.095). Multivariate analysis showed that tumor response to treatment [P = 0.007, RR 2.27 (95% CI, 1.248-4.132)] was the only factor associated with overall survival. All adverse events were tolerable and successfully managed in both treatment groups. CONCLUSIONS: Both HAIC regimens are safe and effective in patients with advanced HCC. High-dose HAIC achieves a better tumor response compared to low-dose HAIC. ; open |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | 373~382 |
| اللغة: | unknown |
| تدمد: | 0344-5704 1432-0843 |
| العلاقة: | CANCER CHEMOTHERAPY AND PHARMACOLOGY; J00437; OAK-2010-01538; https://ir.ymlib.yonsei.ac.kr/handle/22282913/101938Test; http://link.springer.com/article/10.1007%2Fs00280-009-1126-2Test; T201002991; CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.65(2) : 373-382, 2010 |
| DOI: | 10.1007/s00280-009-1126-2 |
| الإتاحة: | https://doi.org/10.1007/s00280-009-1126-2Test https://ir.ymlib.yonsei.ac.kr/handle/22282913/101938Test |
| حقوق: | CC BY-NC-ND 2.0 KR ; https://creativecommons.org/licenses/by-nc-nd/2.0/krTest/ |
| رقم الانضمام: | edsbas.6A0EAA33 |
| قاعدة البيانات: | BASE |
| تدمد: | 03445704 14320843 |
|---|---|
| DOI: | 10.1007/s00280-009-1126-2 |